Collegium contributes to independent education by supporting Continuing Medical Education (CME) and Non-CME Educational Grants.
Areas of interest include, but are not limited to:
- Advance the understanding of the pharmacologic management of chronic pain, including the role of abuse deterrent formulations
- Educate on the effectiveness of opioids in chronic noncancer pain, including long-term use
- Increase awareness and understanding around abuse, misuse, and diversion of prescription opioids
- Improve understanding of the impact of local, state, and federal policy on the treatment of chronic pain, including the impact of policy on abuse deterrent formulations
- Improve patient awareness of options for pharmacologic management of chronic pain, including the use of abuse deterrent formulations
- Research and development of Abuse Deterrent Formulations, including different technologies and types of studies
- Describe trajectories of abuse and addiction, including the potential impact abuse deterrent formulation can have in interrupting this pathway
- Best practices of household risk mitigation for opioid prescribing, including the role of abuse deterrent formulations
As Collegium is a member of the REMS Program Companies (RPCs), any grant request for CME Programs that comply with the Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS), should be submitted directly through the program’s application process. Additional information can be found on the ER/LA Opioid Analgesics REMS website, here.
For additional information on Collegium’s Educational Grant Program, please contact us at: EducationalGrantReviewCommittee@collegiumpharma.com